

PQRS#/ e-CQM CMS#	NQF#	Measure Steward	NQF Domain	Measure Title: Description	Cross Cutting Measure (Y/N)	Measure Type: Process/Outcome (P/O)
N/A	N/A	AAAAI	Communication and Care Coordination	<b>Documentation of Clinical Response to Allergen Immunotherapy within One Year:</b> Percentage of patients aged 5 years and older who were evaluated for clinical improvement and efficacy within one year after initiating allergen immunotherapy AND assessment documented in the medical record	N	P
N/A	N/A	MNCM	Communication and Care Coordination	<b>Penicillin Allergy: Appropriate Removal or Confirmation:</b> Percentage of patients, regardless of age, with a primary diagnosis of penicillin or ampicillin/amoxicillin allergy, who underwent elective skin testing or antibiotic challenge that resulted in the removal of the penicillin or ampicillin/amoxicillin allergy label from the medical record if negative or confirmation of the penicillin or ampicillin/amoxicillin allergy label if positive	N	O
374/50v4	N/A	AMA/PCPI	Communication and Care Coordination	<b>Closing the Referral Loop: Receipt of Specialist Report:</b> Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred.	N	P
226/138v3	28	AAAAI	Community/Population Health	<b>Preventing Care and Screening: Tobacco Use: Screening and Cessation Intervention.</b> Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user.	N	O
402	N/A	AAAAI	Community/Population Health	<b>Tobacco Use and Help with Quitting Among Adolescents:</b> The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user	N	P
111/127v4	43	AAAAI	Community/Population Health	<b>Pneumonia Vaccination Status for Older Adults:</b> Percentage of patients 65 years of age and older who have ever received a pneumococcal vaccine	N	P
128/69v4	421	AAAAI	Community/Population Health	<b>Body Mass Index:</b> Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous six months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous six months of the current encounter Normal Parameters: Age 65 years and older BMI ≥ 23 and < 30 kg/m <sup>2</sup> ; Age 18 – 64 years BMI ≥ 18.5 and < 25 kg/m <sup>2</sup>	N	P
110/147v5	41	AAAAI/ACAAI	Community/Population Health	<b>Preventive Care and Screening: Influenza Immunization:</b> Percentage of patients aged 6 months and older seen for a visit between October 1 and March 31 who received an influenza immunization OR who reported previous receipt of an influenza immunization.	N	P
317/22v4	N/A	AAAAI/ACAAI	Community/Population Health	<b>Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented:</b> Percentage of patients aged 18 years and older seen during the reporting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated	N	P
240/117v4	38	AAAAI/ACAAI	Community/Population Health	<b>Childhood Immunization Status:</b> Percentage of children 2 years of age who had four diphtheria, tetanus and acellular pertussis (DTaP); three polio (IPV), one measles, mumps and rubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); one chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis A (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines by their second birthday.	N	P
53	47	AAAAI/ACAAI	Effective Clinical Care	<b>Pharmacologic Therapy for Persistent Asthma - Ambulatory Care Setting.</b> Percentage of patients aged 5 years and older with a diagnosis of persistent asthma who were prescribed long-term control medication	N	O

398	N/A	AAAAI/ACAAI	Effective Clinical Care	<b>Optimal Asthma Control:</b> Patients ages 5-50 (pediatrics ages 5-17) whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools.	N	P
N/A	N/A	AAAAI/ACAAI	Effective Clinical Care	<b>Assessment of Asthma Control - Ambulatory Care Setting:</b> Percentage of patients aged 5 years and older with a diagnosis of asthma who were evaluated at least once during the measurement period for asthma control (comprising asthma impairment and asthma risk)	N	P
N/A	N/A	AAAAI	Effective Clinical Care	<b>Asthma Assessment and Classification:</b> Percentage of patients aged 5 years and older with asthma and documentation of an asthma assessment and classification	N	O
N/A	N/A	American Academy of Otolaryngology-Head and Neck Surgery	Effective Clinical Care	<b>Lung Function/Spirometry Evaluation:</b> Percentage of patients aged 5 years and older with asthma and documentation of a spirometry evaluation	N	P
N/A	N/A	American Academy of Otolaryngology-Head and Neck Surgery	Effective Clinical Care	<b>Achievement of Projected Effective Dose of Standardized Allergens for Patient Treated With Allergen Immunotherapy for at Least One Year:</b> Proportion of patients receiving subcutaneous allergen immunotherapy that contains at least one standardized extract (mite, ragweed, grass, and/or cat) who achieved the projected effective dose for all included standardized allergen extract(s) after at least one year of treatment	N	P
311/126v4	36	American Academy of Otolaryngology-Head and Neck Surgery	Effective Clinical Care	<b>Use of Appropriate Medications for Asthma:</b> Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period	N	P
N/A	N/A	American Academy of Otolaryngology-Head and Neck Surgery	Efficiency and Cost Reduction	<b>Documented Rationale to Support Long-Term Aeroallergen Immunotherapy Beyond Five Years, as Indicated:</b> Percentage of patients aged 5 years and older who were assessed for clinical rationale prior to continuation of aeroallergen immunotherapy beyond 5 years AND rationale documented in the medical record	N	E
331	N/A	AMA-PCPI	Efficiency and Cost Reduction	<b>Adult Sinusitis: Antibiotic Prescribed for Acute Sinusitis (Appropriate Use):</b> Percentage of patients, aged 18 years and older, with a diagnosis of acute sinusitis who were prescribed an antibiotic within 7 days of diagnosis or within 10 days after onset of symptoms	Y	P
332	N/A	NCQA	Efficiency and Cost Reduction	<b>Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use):</b> Percentage of patients aged 18 years and older with a diagnosis of acute bacterial sinusitis that were prescribed amoxicillin, with or without clavulante, as a first line antibiotic at the time of diagnosis	Y	P
333	N/A	NCQA	Efficiency and Cost Reduction	<b>Adult Sinusitis: Computerized Tomography for Acute Sinusitis (Overuse):</b> Percentage of patients aged 18 years and older with a diagnosis of acute sinusitis who had a computerized tomography (CT) scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis	Y	P
334	N/A	NCQA	Efficiency and Cost Reduction	<b>Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse):</b> Percentage of patients aged 18 years and older with a diagnosis of chronic sinusitis who had more than one CT scan of the paranasal sinuses ordered or received within 90 days after the date of diagnosis	Y	P
65/154v4	69	CMS	Efficiency and Cost Reduction	<b>Appropriate Treatment for Children with Upper Respiratory Infection (URI):</b> Percentage of children 3 months through 18 years of age who were diagnosed with upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or three days after the episode	Y	P
66/146v4	2	AMA-PCPI	Efficiency and Cost Reduction	<b>Appropriate Testing for Children with Pharyngitis:</b> Percentage of children 3-18 years of age who were diagnosed with pharyngitis, ordered an antibiotic and received a group A streptococcus (strep) test for the episode	Y	P
N/A	N/A	NCQA	Patient Safety	<b>Allergen Immunotherapy Treatment: Allergen Specific Immunoglobulin E (IgE) Sensitivity Assessed and Documented Prior to Treatment:</b> Percentage of patients aged 5 years and older who were assessed for IgE sensitivity to allergens prior to initiating allergen immunotherapy AND results documented in the medical record	N	P

N/A	N/A	CMS	Patient Safety	<b>Assessment of Asthma Symptoms Prior to Administration of Allergen Immunotherapy Injection(s):</b> Percentage of patients aged 5 years and older with a diagnosis of asthma who are receiving subcutaneous allergen immunotherapy with a documented assessment of asthma symptoms prior to administration of allergen immunotherapy injections	Y	P
130/68v5	419	CMS	Patient Safety	<b>Documentation of Current Medications in the Medical Record:</b> Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosage, frequency and route of administration	Y	P
238/156v4	22	NCQA	Patient Safety	<b>Use of High-Risk Medications in the Elderly:</b> Percentage of patients 66 years of age and older who were ordered high-risk medications. Two rates are reported. a. Percentage of patients who were ordered at least one high-risk medication. b. Percentage of patients who were ordered at least two different high-risk medications.	N	P
N/A	N/A	NCQA	Person and Caregiver-Centered Experience and Outcomes	<b>Asthma Control: Minimal Important Difference Improvement:</b> Percentage of patients aged 12 years and older whose asthma is not well-controlled as indicated by the Asthma Control Test, Asthma Control Questionnaire, or Asthma Therapy Assessment Questionnaire and who demonstrated a minimal important difference improvement upon a subsequent office visit during the 12-month reporting period	N	P
N/A	N/A	NCQA	Person and Caregiver-Centered Experience and Outcomes	<b>Patient Self-Management and Action Plan:</b> Percentage of patients aged 5 years and older with asthma and documentation of an asthma self-management plan	Y	P
N/A	N/A	NCQA	Person and Caregiver-Centered Experience and Outcomes	<b>Documentation of the Consent Process for Subcutaneous Allergen Immunotherapy in the Medical Record:</b> Percentage of patients aged 5 years and older initiating subcutaneous allergen immunotherapy injections documented to have received education (or their primary caregiver) about possible adverse reactions	N	P

3/15/2016